Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention
· Vyepti® confirms efficacy in new phase III pivotal SUNRISE trial, meeting primary endpoint with statistically significant reductions in mean monthly migraine days compared with placebo · Vyepti® met all key secondary efficacy endpoints in the SUNRISE trial, and the treatment was generally well tolerated · Beginning day 1 after infusion, Vyepti® lead to statistically significant reductions in the risk of experiencing migraine compared to placebo H. Lundbeck A/S (Lundbeck) announced that Vyepti® (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III